Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL)’s traded shares stood at 0.75 million during the last session, with the company’s beta value hitting 1.85. At the close of trading, the stock’s price was $3.06, to imply a decrease of -4.08% or -$0.13 in intraday trading. The ZNTL share’s 52-week high remains $18.07, putting it -490.52% down since that peak but still an impressive 13.07% since price per share fell to its 52-week low of $2.66. The company has a valuation of $218.08M, with an average of 1.19 million shares in intraday trading volume over the past 10 days and average of 1.25 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Zentalis Pharmaceuticals Inc (ZNTL), translating to a mean rating of 1.89. Of 10 analyst(s) looking at the stock, 0 analyst(s) give ZNTL a Sell rating. 0 of those analysts rate the stock as Overweight while 5 advise Hold as 5 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.78.
Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) trade information
After registering a -4.08% downside in the last session, Zentalis Pharmaceuticals Inc (ZNTL) has traded red over the past five days. The 5-day price performance for the stock is 4.44%, and -12.07% over 30 days. With these gigs, the year-to-date price performance is -79.80%. Short interest in Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) saw shorts transact 4.67 million shares and set a 3.17 days time to cover.
The extremes give us $4 and $55 for target low and target high price respectively. As such, ZNTL has been trading -1697.39% off suggested target high and -30.72% from its likely low.
Zentalis Pharmaceuticals Inc (ZNTL) estimates and forecasts
Looking at statistics comparing Zentalis Pharmaceuticals Inc share performance against respective industry, we note that the company has outperformed competitors. Zentalis Pharmaceuticals Inc (ZNTL) shares are -25.18% down over the last 6 months, with its year-to-date growth rate higher than industry average at 44.52% against 16.60%.
ZNTL Dividends
Zentalis Pharmaceuticals Inc has its next earnings report out in January. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL)’s Major holders
Zentalis Pharmaceuticals Inc insiders hold 9.45% of total outstanding shares, with institutional holders owning 98.01% of the shares at 108.24% float percentage. In total, 98.01% institutions holds shares in the company, led by MATRIX CAPITAL MANAGEMENT COMPANY, LP. As of 2024-06-30, the company held over 13.96 million shares (or 19.6902% of shares), all amounting to roughly $57.1 million.
The next major institution holding the largest number of shares is FMR LLC with 8.68 million shares, or about 12.2383% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $35.49 million.
We also have Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund and Mutual Fund Ser Tr-Eventide Gilead Fund as the top two Mutual Funds with the largest holdings of the Zentalis Pharmaceuticals Inc (ZNTL) shares. Going by data provided on Sep 30, 2024 , Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund holds roughly 4.95 shares. This is just over 6.94% of the total shares, with a market valuation of $15.14 million. Data from the same date shows that the other fund manager holds a little less at 3.58, or 5.03% of the shares, all valued at about 10.97 million.
